IE 11 is not supported. For an optimal experience visit our site on another browser.

SIGA to Discuss Third Quarter Results of Operations on November 2, 2010

NEW YORK, Oct. 29, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report third quarter 2010 results on Tuesday, November 2, 2010.
/ Source: GlobeNewswire

NEW YORK, Oct. 29, 2010 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, announced today that it will report third quarter 2010 results on Tuesday, November 2, 2010.

Management will host a conference call and simultaneous webcast to discuss the results of operations and provide an update on recent business developments at 4:30 P.M. ET on Tuesday, November 2, 2010. Participants should call (877) 564-1219 (United States/Canada) or (973) 638-3429 (International) and request the SIGA call or provide confirmation code 22244336. A live broadcast of the call will be available on the Company's website at www.SIGA.com under the 'Events & Presentations' tab in the Investor Relations section.

A replay of the call will be available approximately two hours after the call and will be accessible until 11:59 p.m. on Tuesday, November 9, 2010. To listen to the replay, dial (800) 642-1687 (domestic) or (706) 645-9291 (international) and enter the pass code 22244336. The webcast of the event will also be archived on the Company's website for one year under the 'Events & Presentations' tab in the Investor Relations section.

About SIGA Technologies, Inc.

SIGA Technologies is applying viral and bacterial genomics and sophisticated computational modeling in the design and development of novel products for the prevention and treatment of serious infectious diseases, with an emphasis on products for biological warfare defense. SIGA believes that it is a leader in the development of pharmaceutical agents to fight potential bio-warfare pathogens. SIGA has antiviral programs targeting smallpox and other Category A pathogens, including arenaviruses (Lassa fever, Junin, Machupo, Guanarito, Sabia, and lymphocytic choriomeningitis), dengue virus, and the filoviruses (Ebola and Marburg). For more information about SIGA, please visit SIGA's web site at http://www.siga.com/.

The SIGA Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4504

CONTACT: KCSA Strategic Communications Todd Fromer 212-896-1215 Tfromer@kcsa.com Marybeth Csaby 212-896-1236 mcsaby@kcsa.com